tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Value
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News WireArrivedEquityMultiple
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Smart Value
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

RARE Stock Latest News

Ultragenyx price target raised to $117 from $104 at JPMorgan
The FlyUltragenyx price target raised to $117 from $104 at JPMorgan
4d ago
RARE
Rezolute appoints Erik Harris to board of directors
PremiumThe Fly
Rezolute appoints Erik Harris to board of directors
5d ago
RARE
RZLT
Ultragenyx price target lowered to $115 from $140 at Piper Sandler
PremiumThe Fly
Ultragenyx price target lowered to $115 from $140 at Piper Sandler
14d ago
RARE
Ultragenyx assumed with an Overweight at Morgan Stanley
PremiumThe Fly
Ultragenyx assumed with an Overweight at Morgan Stanley
24d ago
RARE
Ultragenyx Pharmaceutical: Strong Buy Rating Backed by Growth Potential and Robust Pipeline
PremiumRatings
Ultragenyx Pharmaceutical: Strong Buy Rating Backed by Growth Potential and Robust Pipeline
24d ago
RARE
Optimistic Outlook for Ultragenyx Pharmaceutical Amid Promising Gene Therapy Developments
PremiumRatingsOptimistic Outlook for Ultragenyx Pharmaceutical Amid Promising Gene Therapy Developments
1M ago
RARE
Ultragenyx’s BLA for UX111 accepted by FDA for priority review
Premium
The Fly
Ultragenyx’s BLA for UX111 accepted by FDA for priority review
1M ago
RARE
Ultragenyx price target raised to $136 from $121 at Canaccord
Premium
The Fly
Ultragenyx price target raised to $136 from $121 at Canaccord
1M ago
RARE
3 Best Stocks to Buy Now, 2/18/2025, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Now, 2/18/2025, According to Top Analysts
1M ago
HL
RARE
Ultragenyx Pharmaceutical: Strong Growth Prospects and Pipeline Advancements Reinforce Buy Rating
PremiumRatings
Ultragenyx Pharmaceutical: Strong Growth Prospects and Pipeline Advancements Reinforce Buy Rating
1M ago
RARE
Ultragenyx Reports Strong Growth Amid Challenges
PremiumCompany Announcements
Ultragenyx Reports Strong Growth Amid Challenges
1M ago
RARE
Ultragenyx price target raised to $86 from $73 at TD Cowen
PremiumThe Fly
Ultragenyx price target raised to $86 from $73 at TD Cowen
2M ago
RARE
Ultragenyx Pharmaceutical: Promising Growth Prospects with Strong Financial Outlook and Key Pipeline Developments
PremiumRatingsUltragenyx Pharmaceutical: Promising Growth Prospects with Strong Financial Outlook and Key Pipeline Developments
2M ago
RARE
Promising Developments in Ultragenyx Pharmaceuticals Drive Ed Arce’s Buy Rating
Premium
Ratings
Promising Developments in Ultragenyx Pharmaceuticals Drive Ed Arce’s Buy Rating
2M ago
RARE
Ultragenyx Pharmaceutical Reports Strong 2024 Growth
Premium
Company Announcements
Ultragenyx Pharmaceutical Reports Strong 2024 Growth
2M ago
RARE
Ultragenyx Pharmaceutical’s Strong Sales and Promising Pipeline Support Buy Rating
PremiumRatings
Ultragenyx Pharmaceutical’s Strong Sales and Promising Pipeline Support Buy Rating
2M ago
RARE
Ultragenyx reports Q4 EPS ($1.39), consensus ($1.27)
PremiumThe Fly
Ultragenyx reports Q4 EPS ($1.39), consensus ($1.27)
2M ago
RARE
Ultragenyx sees FY25 revenue $640M-$670M, consensus $651.93M
PremiumThe Fly
Ultragenyx sees FY25 revenue $640M-$670M, consensus $651.93M
2M ago
RARE
RARE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
RARE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
RARE
Ultragenyx Pharmaceuticals: Buy Rating Supported by Promising Gene Therapy Trial Results and Regulatory Advancements
PremiumRatingsUltragenyx Pharmaceuticals: Buy Rating Supported by Promising Gene Therapy Trial Results and Regulatory Advancements
2M ago
RARE
Ultragenyx Pharmaceutical’s UX111 Poised for Success: Buy Recommendation Backed by Promising Clinical Data and Strong Pipeline
Premium
Ratings
Ultragenyx Pharmaceutical’s UX111 Poised for Success: Buy Recommendation Backed by Promising Clinical Data and Strong Pipeline
2M ago
RARE
Ultragenyx announces new data on UX111 AV gene therapy
Premium
The Fly
Ultragenyx announces new data on UX111 AV gene therapy
2M ago
RARE

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >